Dayton Therapeutics

What Dayton Therapeutics does

Dayton Therapeutics AG is a clinical-stage Swiss oncology company founded in 2020 and headquartered in Steinhausen, Zug, Switzerland. It identifies and develops clinical compounds for cancer indications with limited therapeutic options, using a drug-repurposing model that adapts existing compounds for new oncology indications rather than pursuing de novo discovery.

The company's core technology is the proprietary 'Onco-indication Engine,' which combines oncologist expertise with AI and data mining to systematically surface high-yield candidates for cancer indications with large unmet medical need. The company reports positive experience with two compounds, which serves as the engine's proof of concept and the basis for planned scaling. Dayton Therapeutics describes a 'risk-mitigated pipeline' of future therapeutic launches as the principal output of the engine.

Commercially, Dayton Therapeutics operates as a clinical-stage biopharma without disclosed revenue, pricing, partnerships, or funding rounds in the available data. The team comprises four named executives (CEO, CMO, CFO, CSO) supported by 1-10 total employees. The go-to-market model is implicitly clinical-development driven, with engagement via clinical trial sites, healthcare providers, and regulatory bodies rather than traditional product distribution. No customers, awards, patents, certifications, or trial milestones are publicly disclosed in the source material.

Name

Dayton Therapeutics

Legal name

Dayton Therapeutics AG

Website

https://daytontherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Dayton Therapeutics AG is a clinical-stage Swiss oncology company that uses its proprietary 'Onco-indication Engine,' combining oncologist expertise with AI and data mining, to repurpose existing compounds for new cancer indications with limited therapeutic options.

Ownership category

akta.pro rank

Product category

Clinical Oncology Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Drug repurposing
• Clinical oncology
• AI drug discovery
• Cancer therapeutics
• Compound identification

Headquarters

HQ city

Steinhausen

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Dayton Therapeutics is a clinical oncology company that identifies and develops clinical-stage compounds for the treatment of new cancer indications with limited therapeutic options, doing so by scaling up its proprietary Onco-indication Engine — a platform that combines oncologist know-how with AI and data mining to systematically pursue high-yield candidates for cancer indications of large unmet medical need. By adapting existing drugs for new oncology indications, the company maximizes the utility of drug development and provides a risk-mitigated pipeline of future therapeutic launches; two compounds have already generated positive proof-of-concept experience.

Product overview

Dayton Therapeutics operates as a clinical oncology company offering a unified product approach centered on its proprietary Onco-indication Engine. This AI and data mining-augmented platform identifies and develops clinical compounds for cancer indications with limited therapeutic options. The company maximizes drug development utility by adapting existing drugs for new oncology indications, creating a risk-mitigated pipeline of compounds for future launches.

Differentiator

Problem solved

Functional benefit

Products and services

• Onco-indication Engine A proprietary platform that combines oncologist know-how with AI and data mining to systematically identify and develop clinical compounds for new cancer indications with limited therapeutic options; serves as Dayton Therapeutics' core drug repurposing methodology and source of its pipeline.
• Clinical Compounds Pipeline Drug candidates identified and developed through the Onco-indication Engine for oncology indications with large unmet medical need, including two compounds with positive proof-of-concept experience; intended for healthcare providers and oncology treatment centers via licensing and clinical development partnerships.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves3 records

Expansion highlights2 records

Direct peers

• Insilico Medicine: Clinical-stage AI biotech applying deep learning and omics data mining to oncology and aging-related indications, using proprietary target-discovery engines — comparable to Dayton's oncologist-augmented AI approach.
• Lantern Pharma: Clinical-stage oncology company using an AI and data-driven platform (RADR) to identify and develop oncology drug candidates, including through drug rescue and repurposing — closely aligned with Dayton's repurposing-thesis engine.
• Recursion Pharmaceuticals: AI-driven clinical-stage drug discovery platform applying machine learning and data mining to identify novel therapeutic candidates across oncology and rare disease — the closest analogue to Dayton's Onco-indication Engine at greater scale.
• Exscientia: AI-native pharmatech using data-driven platforms to design and prioritize clinical drug candidates, including in oncology — directly comparable in combining AI with proprietary biology to systematically generate pipeline assets.

Emerging players

• Tyme Technologies: Clinical-stage oncology company developing cancer therapeutics with a pipeline-based model — comparable as a small, pipeline-driven oncology biotech.
• Notable Labs (SEngine Precision Medicine): AI-enabled precision oncology platform identifying patient-specific drug response and repurposing opportunities — comparable AI/data-mining approach applied to oncology indications.
• Iterion Therapeutics: Clinical-stage oncology biotech focused on advancing a pipeline of cancer therapeutics — comparable early-stage clinical oncology developer profile.
• Bexion Pharmaceuticals: Early clinical-stage oncology biotech with a focused pipeline, comparable to Dayton as a small-cap clinical oncology developer.
• Pangea Biomed / Mind the Byte (drug-repurposing players): AI-driven precision oncology platform that re-prioritizes existing and clinical-stage drugs for oncology indications — directly aligned with Dayton's repurposing-for-cancer-indications thesis.

Broad incumbents

• BenevolentAI: Large AI-driven drug discovery company with clinical programs spanning multiple indications, including oncology — comparable in using AI/data-mining to systematically generate clinical assets, though with broader scope than Dayton.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/DaytonThx

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dayton Therapeutics